CURE Magazine and curetoday.com Are Under New Management
December 01, 2014 – Mike Hennessy
Updates from the European Society for Medical Oncology
December 01, 2014 – Staff Reports
A Breast Cancer Alphabet
December 01, 2014 – Katherine Lagomarsino
Primary Care After Cancer Treatment
December 01, 2014 – Len Lichtenfeld, MD
TheAnswertoCancer.org
December 01, 2014 – Elizabeth Whittington
Adult Female Survivors at Risk for Sexual Issues
December 01, 2014 – Katherine Lagomarsino
Yoga's Benefits Explored
December 01, 2014 – Kathy LaTour
Harmony Hill Retreat Center
December 01, 2014 – Elizabeth Whittington
Sunshine Act Sheds Light on Gifts to Doctors From Pharmaceutical Companies
December 01, 2014 – Lena Huang
Cancer Center Fundraiser was de la Renta's Farewell
December 01, 2014 – Elizabeth Whittington
Few Aware that Dense Breasts Increase Cancer Risk
December 01, 2014 – Beth Fand Incollingo
Surviving Caregiving
November 25, 2014 – Kathy LaTour
B-Cell Lymphomas: A Long and Winding Road
November 25, 2014 – Heather L. Van Epps, PhD
The Fitness Factor
November 24, 2014 – Laura Beil
Bad Behavior
November 24, 2014 – Jeannette Moninger
Helping Children Heal
November 24, 2014 – Maureen Salamon
Recovering from Brain Cancer Surgery Takes Time
November 24, 2014 – Jennifer L. W. Fink, RN
Rare Finds: A Rare Cancer Diagnosis
November 24, 2014 – Charlotte Huff
Guy's Guide
November 24, 2014 – Michael Irving
Chewing the Fat
November 24, 2014 – Katy Human
NORD Offers Information and Support for Patients of Rare Cancers
November 24, 2014 – Peter L. Saltonstall
Managing Thrombocytopenia
November 24, 2014 – Lacey Marlow
FDA Aims to Start Regulating Custom Diagnostic Tests
November 24, 2014 – Susan Kreimer
A Focus on a Cure for Non-Hodgkin Lymphoma
November 22, 2014 – Debu Tripathy, MD
Comments From Readers
November 21, 2014
FDA Approves New Uses for Existing Cancer Treatments
November 22, 2014 – Staff Reports
CURE Magazine and curetoday.com Are Under New Management
December 01, 2014 – Mike Hennessy
Updates from the European Society for Medical Oncology
December 01, 2014 – Staff Reports
A Breast Cancer Alphabet
December 01, 2014 – Katherine Lagomarsino
Primary Care After Cancer Treatment
December 01, 2014 – Len Lichtenfeld, MD
TheAnswertoCancer.org
December 01, 2014 – Elizabeth Whittington
Adult Female Survivors at Risk for Sexual Issues
December 01, 2014 – Katherine Lagomarsino
Yoga's Benefits Explored
December 01, 2014 – Kathy LaTour
Harmony Hill Retreat Center
December 01, 2014 – Elizabeth Whittington
Sunshine Act Sheds Light on Gifts to Doctors From Pharmaceutical Companies
December 01, 2014 – Lena Huang
Cancer Center Fundraiser was de la Renta's Farewell
December 01, 2014 – Elizabeth Whittington
Few Aware that Dense Breasts Increase Cancer Risk
December 01, 2014 – Beth Fand Incollingo
Surviving Caregiving
November 25, 2014 – Kathy LaTour
B-Cell Lymphomas: A Long and Winding Road
November 25, 2014 – Heather L. Van Epps, PhD
The Fitness Factor
November 24, 2014 – Laura Beil
Bad Behavior
November 24, 2014 – Jeannette Moninger
Helping Children Heal
November 24, 2014 – Maureen Salamon
Recovering from Brain Cancer Surgery Takes Time
November 24, 2014 – Jennifer L. W. Fink, RN
Rare Finds: A Rare Cancer Diagnosis
November 24, 2014 – Charlotte Huff
Guy's Guide
November 24, 2014 – Michael Irving
Chewing the Fat
November 24, 2014 – Katy Human
NORD Offers Information and Support for Patients of Rare Cancers
November 24, 2014 – Peter L. Saltonstall
Managing Thrombocytopenia
November 24, 2014 – Lacey Marlow
FDA Aims to Start Regulating Custom Diagnostic Tests
November 24, 2014 – Susan Kreimer
Currently Viewing
A Focus on a Cure for Non-Hodgkin Lymphoma
November 22, 2014 – Debu Tripathy, MD
FDA Approves New Uses for Existing Cancer Treatments
November 22, 2014 – Staff Reports

A Focus on a Cure for Non-Hodgkin Lymphoma

Most non-Hodgkin lymphomas can be cured, but new drugs are needed.
BY Debu Tripathy, MD
PUBLISHED November 22, 2014
This issue is our first in CURE’s new home, with a welcome to new team members and best wishes to some of our editorial members who are now departing. Our mission remains the same—to cover both the science and humanity of the field of cancer.

Our winter 2014 issue is a reflection of topics requested by our readers, our advisory board of cancer experts and our editorial staff. Our feature story on lymphoma deserves some additional mention. Non-Hodgkin lymphoma is not the most common of cancers, but it has garnered attention in the medical field because of its interesting biology, and shortly after the last mid-century, its sudden curability with the advent of combination chemotherapy. Any oncologist will tell you that the board exam questions are represented disproportionately by lymphoma questions, because it is critical that doctors be proficient in their knowledge regarding the most curable diseases. I was fascinated in medical school when my instructor at Duke University, Michael Borowitz, explained new classifications of lymphoma based on the class of malignant lymphocytes determined by antibody staining—an area that he was just beginning to pioneer in the early 1980s. He is now a professor at Johns Hopkins University, and the field of lymphoma continues to advance at a rapid clip.

Thankfully, most cases are now cured, but there is still a need in cases that relapse or never respond to chemotherapy. One of the first targeted drugs, Rituxan (rituximab), an antibody to the lymphocyte receptor CD20, was approved in 1997 and continues to be a key contributor to the treatment of B-cell lymphocyte malignancies that express CD20. But we also highlight several newer drugs in this issue, including other antibodies to CD20 and to other B-cell surface proteins, similar antibodies bound to radioactive particles, and drugs that block growth signals initiated by receptors on lymphoma cells. Can the use of these drugs earlier in the course of a disease make it more curable? Can we learn more about lymphoma and come up with new treatments? Research will answer those questions. We have come a long way, but we still have some distance to go.

Debu Tripathy, MD
Editor-in-Chief
Professor of Medicine Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Non-Hodgkin Lymphoma CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In